LeMaitre Vascular (NASDAQ:LMAT) Issues Q2 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its second quarter 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.790-0.840 for the period, compared to the consensus EPS estimate of 0.760. The company issued revenue guidance of $70.5 million-$72.5 million, compared to the consensus revenue estimate of $71.5 million. LeMaitre Vascular also updated its FY 2026 guidance to 2.930-3.080 EPS.

LeMaitre Vascular Trading Down 2.1%

NASDAQ LMAT traded down $2.31 during trading hours on Thursday, hitting $107.91. 363,632 shares of the company were exchanged, compared to its average volume of 182,455. The stock has a 50-day moving average price of $110.00 and a 200 day moving average price of $94.48. The company has a quick ratio of 10.95, a current ratio of 14.32 and a debt-to-equity ratio of 0.42. LeMaitre Vascular has a 52 week low of $78.35 and a 52 week high of $118.01. The stock has a market cap of $2.47 billion, a PE ratio of 39.82, a price-to-earnings-growth ratio of 3.06 and a beta of 0.60.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The business had revenue of $66.55 million during the quarter, compared to analyst estimates of $66.67 million. During the same quarter in the previous year, the business earned $0.48 earnings per share. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Analysts forecast that LeMaitre Vascular will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Thursday, May 21st will be given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Thursday, May 21st. LeMaitre Vascular’s payout ratio is 36.90%.

Wall Street Analysts Forecast Growth

LMAT has been the subject of several recent analyst reports. Wells Fargo & Company boosted their target price on LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a research report on Wednesday. Weiss Ratings lowered LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday. Wall Street Zen upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Roth Mkm restated a “buy” rating and set a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Finally, Zacks Research upgraded LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and a consensus price target of $112.60.

Insider Activity at LeMaitre Vascular

In related news, Director David B. Roberts sold 8,464 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $106.80, for a total value of $903,955.20. Following the completion of the sale, the director owned 17,979 shares in the company, valued at approximately $1,920,157.20. The trade was a 32.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Trent G. Kamke sold 1,044 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $110.29, for a total value of $115,142.76. Following the completion of the sale, the insider owned 6,677 shares of the company’s stock, valued at $736,406.33. The trade was a 13.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 215,438 shares of company stock worth $23,062,911. Company insiders own 7.40% of the company’s stock.

LeMaitre Vascular News Roundup

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Several firms raised price targets and issued upbeat notes, supporting upside. Barrington raised its target to $120 and reiterates an outperform view. Barrington Research Raises Target
• Positive Sentiment: Citizens JMP lifted its target to $127 and kept a market‑outperform stance, the most bullish target among recent updates. Citizens JMP Raises Target
• Positive Sentiment: Zacks upgraded LMAT to a Rank #2 (Buy) and published a bullish piece highlighting growth characteristics that could attract investors. LeMaitre (LMAT) Upgraded to Buy: Here’s Why
• Positive Sentiment: Company Q1 results beat EPS estimates modestly and management gave FY‑2026 EPS guidance of $2.93–$3.08 (Q2 guidance $0.79–$0.84), supporting higher analyst valuations around ~$118 consensus. Strong margins and revenue growth underpinned the upbeat notes. US$118 – That’s What Analysts Think…
• Positive Sentiment: LeMaitre declared a quarterly dividend ($0.25/share), modestly supportive for income-minded investors and signaling confidence in cash flow. (Ex‑dividend May 21.)
• Neutral Sentiment: Management will present at the Bank of America Healthcare Conference on May 13 — an opportunity for investor Q&A but not a guaranteed catalyst. LeMaitre to Present at the Bank of America Healthcare Conference
• Neutral Sentiment: Wells Fargo raised its target to $104 but kept an Equal Weight rating — the move is less bullish than other shops and reflects mixed analyst views on near‑term upside. Wells Fargo Target Raise
• Neutral Sentiment: The Q1 earnings call transcript and deep‑dive coverage outline drivers — Artegraft expansion and pricing helped margins — but also note cautious market reaction; useful reading for investors deciding whether margins and growth justify the higher multiples. Q1 2026 Earnings Call Transcript LMAT Q1 deep dive…
• Negative Sentiment: Despite the positive notes, some coverage and market participants remain cautious about sustainability of margin gains and valuation (mixed analyst ratings persist), which likely contributed to the share pullback today.

Institutional Trading of LeMaitre Vascular

Large investors have recently modified their holdings of the company. Mercer Global Advisors Inc. ADV lifted its holdings in LeMaitre Vascular by 11.5% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 3,606 shares of the medical instruments supplier’s stock worth $292,000 after buying an additional 371 shares during the period. NewEdge Advisors LLC lifted its holdings in LeMaitre Vascular by 4.6% during the fourth quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock worth $256,000 after buying an additional 139 shares during the period. Empowered Funds LLC purchased a new stake in LeMaitre Vascular during the fourth quarter worth $289,000. nVerses Capital LLC purchased a new stake in LeMaitre Vascular during the fourth quarter worth $234,000. Finally, Voloridge Investment Management LLC lifted its holdings in LeMaitre Vascular by 70.0% during the fourth quarter. Voloridge Investment Management LLC now owns 62,909 shares of the medical instruments supplier’s stock worth $5,102,000 after buying an additional 25,901 shares during the period. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.